Masimo (NSDQ:MASI) and Royal Philips (NYSE:PHG) announced today that Philips will integrate additional Masimo measurement technologies into certain IntelliVue MX-series monitors to help clinicians assess cerebral oximetry and ventilation status.
Masimo noninvasive measurements, such as SET measure-through motion and Low Perfusion pulse oximetry and advanced rainbow SET Pulse CO-Oximetry parameters like noninvasive hemoglobin (SpHb), have long been available on a wide range of Philips multi-parameter monitors.
In 2016, Masimo and Philips entered into a multi-year business partnership with Philips agreeing to integrate Masimo’s SedLine brain function monitoring, O3 regional oximetry and Nomoline capnography tech into certain Philips IntelliVue monitors.
The latest agreement will add Masimo’s NomoLine and O3 measurements to Philips patient monitors to provide capnography and regional cerebral oximetry.
NomoLine capnography and O3 regional oximetry measurements are available now on Philips MX500 and MX550 monitors outside the U.S. and are also available directly from Masimo on its Root patient monitoring and connectivity platform and when connected to select Philips patient monitors via Philips’ IntelliBridge module.
NomoLine “no-moisture” sampling lines are designed for low-flow applications and can be used in a variety of clinical scenarios and care settings, on both intubated and non-intubated patients of all ages, in both low- and high-humidity applications. O3 regional oximetry may help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain, according to Masimo.
“We are delighted to reinforce our partnership with Masimo, bringing their advanced measurements to our innovative IntelliVue patient monitors, thereby making them even more versatile,” said Philips CEO Frans van Houten in a news release. “Our customers expect integrated solutions to help them address the quadruple aim of healthcare. The complementary strengths of Philips and Masimo allow us to offer reliable ventilation and regional oximetry solutions, which we expect will help clinicians deliver even better patient care.”
“Combining our expertise in noninvasive monitoring and signal processing technologies with Philips’ expertise in integrated patient monitoring and therapy solutions is a win-win for patients and clinicians alike,” added Masimo CEO Joe Kiani. “We are proud that Philips, recognizing our expertise in this clinical space, has chosen to make our innovative O3 and NomoLine platforms available to their customers. We look forward to continuing our partnership with a focus on improving patient outcomes and reducing the cost of care.”